{"id":"axs-07-meloxicam-rizatriptan","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Paresthesia"},{"rate":null,"effect":"Chest discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meloxicam inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin-mediated inflammation and pain signaling. Rizatriptan acts as a selective agonist at serotonin 5-HT1B and 5-HT1D receptors on cranial blood vessels and trigeminal nerve terminals, causing vasoconstriction and suppressing pain transmission. The combination leverages both anti-inflammatory and vasoconstrictor mechanisms for enhanced migraine relief.","oneSentence":"AXS-07 combines meloxicam (an NSAID) with rizatriptan (a 5-HT1B/1D receptor agonist) to treat acute migraine by reducing inflammation and constricting cranial blood vessels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:16.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute migraine with or without aura"}]},"trialDetails":[{"nctId":"NCT04163185","phase":"PHASE3","title":"Initiating Early Control of Migraine Pain and Associated Symptoms","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-10-08","conditions":"Migraine","enrollment":302},{"nctId":"NCT05550207","phase":"PHASE3","title":"Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2022-08-31","conditions":"Migraine","enrollment":100},{"nctId":"NCT04068051","phase":"PHASE3","title":"Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-07-06","conditions":"Migraine","enrollment":706},{"nctId":"NCT03896009","phase":"PHASE3","title":"Maximizing Outcomes in Treating Acute Migraine","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-03-04","conditions":"Migraine","enrollment":1594}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AXS-07 (meloxicam-rizatriptan)","genericName":"AXS-07 (meloxicam-rizatriptan)","companyName":"Axsome Therapeutics, Inc.","companyId":"axsome-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AXS-07 combines meloxicam (an NSAID) with rizatriptan (a 5-HT1B/1D receptor agonist) to treat acute migraine by reducing inflammation and constricting cranial blood vessels. Used for Acute migraine with or without aura.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}